Effects of Arabinoxylan-Oligosaccharides Compared to Other Prebiotics in Healthy Subjects
NCT ID: NCT00853034
Last Updated: 2009-02-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
20 participants
INTERVENTIONAL
2006-10-31
2007-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
FOS-IN
prebiotic fructo-oligosaccharide enriched inulin
FOS-IN
prebiotic fructo-oligosaccharide enriched inulin
intake period: 2 weeks, 1.25 or 2.50g every morning and evening
AXOS
arabinoxylan-oligosaccharides (AXOS)
AXOS
arabinoxylan-oligosaccharides (AXOS)
intake period: 2 weeks, 1.25 or 2.50g every morning and evening
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
FOS-IN
prebiotic fructo-oligosaccharide enriched inulin
intake period: 2 weeks, 1.25 or 2.50g every morning and evening
AXOS
arabinoxylan-oligosaccharides (AXOS)
intake period: 2 weeks, 1.25 or 2.50g every morning and evening
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-45 years
* regular eating pattern
Exclusion Criteria
* antibiotic intake
* medication influencing gut transit or microbiota
* abdominal surgery
* pregnancy
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
KU Leuven
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kristin Verbeke, PhD
Role: STUDY_DIRECTOR
KU Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Gastrointestinal Research, Laboratory Digestion and Absorption
Leuven, Leuven, Belgium
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cloetens L, De Preter V, Swennen K, Broekaert WF, Courtin CM, Delcour JA, Rutgeerts P, Verbeke K. Dose-response effect of arabinoxylooligosaccharides on gastrointestinal motility and on colonic bacterial metabolism in healthy volunteers. J Am Coll Nutr. 2008 Aug;27(4):512-8. doi: 10.1080/07315724.2008.10719733.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AXOS 001
Identifier Type: -
Identifier Source: org_study_id